Guinea Introduces Malaria Vaccine into Routine Immunization: A Major Turning Point in the Fight Against Malaria

Strategic Insights -

Guinea has become the latest country to introduce the RTS, S malaria vaccine into its routine immunization program, marking a significant milestone in the fight against malaria, which remains a leading cause of child morbidity and mortality in the country. Under the leadership of the Ministry of Health and Public Hygiene, and with the support of Gavi, the Vaccine Alliance, the World Health Organization (WHO), UNICEF, and PATH, the vaccine will be available in four districts with moderate to high transmission, covering approximately 60,000 children eligible for vaccination each year. The vaccine will be administered to all children aged 5 to 11 months, with four doses required for optimal protection. Guinea joins a growing group of African countries that have integrated the malaria vaccine into their national immunization programs, underscoring the country's commitment to strengthening its health system and improving access to essential healthcare.

Key Takeaways:

  • Guinea has become the 21st African country to introduce the RTS, S malaria vaccine into its routine immunization program.
  • The vaccine will be available in four districts with moderate to high transmission, covering approximately 60,000 children eligible for vaccination each year.
  • The vaccine will be administered to all children aged 5 to 11 months, with four doses required for optimal protection.
  • The introduction of the vaccine is part of an integrated approach to malaria control, combining prevention, treatment, vaccination, and community awareness.
  • The vaccine has been shown to be safe and effective in reducing malaria cases by over 75% in areas of highly seasonal transmission.
  • The vaccine will be completely free and will not replace other prevention methods such as insecticide-treated nets.
  • Gavi aims to fully vaccinate over 50 million children between 2026 and 2030.
  • The recommended vaccination schedule in Guinea is consistent with international guidelines and is designed to provide optimal protection against malaria.
  • The introduction of the vaccine is a major turning point in the fight against malaria, which remains the leading cause of child morbidity and mortality in Guinea.

Statistics:

  • 4.43 million malaria cases were recorded in Guinea in 2023, according to the 2024 WHO World Malaria Report.
  • Malaria accounts for more than a third of consultations and hospitalizations in public health facilities in Guinea.
  • The parasite prevalence in children under five years of age was 17% in 2023, with a higher prevalence in some areas such as Guinea Forestiere.
  • The vaccine has reduced malaria cases by over 75% in areas of highly seasonal transmission.
  • Over 24 million doses of the malaria vaccine have been delivered to 21 African countries through Gavi-supported routine immunization programs.
  • The vaccine has been given to millions of children and is safe and effective.

Sources:

  • Gavi, the Vaccine Alliance
  • World Health Organization (WHO)
  • UNICEF
  • PATH
  • WHO World Malaria Report 2024
  • Gavi press release, August 13, 2023
  • PATH website
  • UNICEF website
  • WHO website
  • Gavi website